Impact of pharmacist-led interventions on medication-related problems among patients treated for cancer: A systematic review and meta-analysis of randomized control trials

Fentie, Atalay Mulu; Huluka, Solomon Assefa; Gebremariam, Girma Tekle; Gebretekle, Gebremedhin Beedemariam; Abebe, Ephrem; Fenta, Teferi Gedif

doi:10.1016/j.sapharm.2024.02.006

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of pharmacist interventions on adult outpatients with cancer was summarized in several systematic reviews with the result that the interventions could improve outcome measures like rates of nausea, vomiting and pain control, medication adherence, patient satisfaction, quality of life, and cost savings [ 25 , 26 , 27 , 28 ]. A positive effect on the number of DRPs, clinical outcomes, and care processes was also shown in several studies [ 6 , 18 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer

Günther,

Schuler,

Hentschel

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: We aimed to assess medication risks and determine factors influencing the health-related quality of life (HRQOL) in cancer inpatients. Methods: A retrospective analysis was conducted to identify drug-related problems (DRPs) based on medication reviews, including patient-reported outcomes (PROs). Multiple linear regression analyses were performed to identify sociodemographic, disease-related, and drug therapy-related factors influencing changes from hospital admission to discharge in the scales of the EORTC QLQ-C30 questionnaire. Results: A total of 162 inpatients with various hematological and solid cancer diseases was analyzed. Patients received a mean of 11.6 drugs and 92.6% of patients exhibited polymedication resulting in a mean of 4.0 DRPs per patient. Based on PRO data, 21.5% of DRPs were identified. Multiple linear regression models described the variance of the changes in global HRQOL and physical function in a weak-to-moderate way. While drug therapy-related factors had no influence, relapse status and duration of hospital stay were identified as significant covariates for global HRQOL and physical function, respectively. Conclusion: This analysis describes underlying DRPs in a German cancer inpatient population. PROs provided valuable information for performing medication reviews. The multiple linear regression models for global HRQOL and physical function provided explanations for changes during hospital stay.

show abstract